Puma Biotechnology - PBYI Stock Forecast, Price & News

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Wall Street Analysts Forecast Growth

PBYI has been the topic of several recent research reports. StockNews.com upgraded shares of Puma Biotechnology from a "hold" rating to a "buy" rating in a research report on Monday, August 8th. HC Wainwright decreased their target price on shares of Puma Biotechnology from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, August 5th.

Puma Biotechnology Price Performance

NASDAQ:PBYI traded down $0.18 on Tuesday, reaching $3.27. The stock had a trading volume of 248,035 shares, compared to its average volume of 469,216. The company has a market capitalization of $148.97 million, a P/E ratio of -3.80 and a beta of 0.66. Puma Biotechnology has a 1-year low of $1.60 and a 1-year high of $7.84. The company has a quick ratio of 1.89, a current ratio of 2.01 and a debt-to-equity ratio of 4.95. The stock has a fifty day moving average price of $3.02 and a 200-day moving average price of $2.67.

Insider Buying and Selling at Puma Biotechnology

In other Puma Biotechnology news, Director Michael Patrick Miller sold 25,000 shares of the business's stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $3.55, for a total value of $88,750.00. Following the transaction, the director now directly owns 54,858 shares in the company, valued at $194,745.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Michael Patrick Miller sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $3.55, for a total transaction of $88,750.00. Following the transaction, the director now directly owns 54,858 shares in the company, valued at $194,745.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Alan H. Auerbach sold 26,140 shares of the company's stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $2.63, for a total transaction of $68,748.20. Following the transaction, the chief executive officer now owns 6,317,952 shares in the company, valued at $16,616,213.76. The disclosure for this sale can be found here. Insiders have sold a total of 92,372 shares of company stock worth $263,663 over the last ninety days. Corporate insiders own 21.20% of the company's stock.